SCHEMBL875993

SCHEMBL875993

Cn1nc(C(F)F)c(C(=O)O)c1Oc1cccc(C(F)F)c1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 9/20 0.71
PTGER2 P43116 1/20 0.58
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
PTGS1 P23219 1/20 0.42
MEN1 O00255 1/20 0.39
CYP2D6 P10635 1/20 0.39
KMT2A Q03164 1/20 0.39
ALOX5 P09917 1/20 0.38
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
FAAH O00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26418788 0.95 PTGER4 (0.66) PTGER4PTGER2KDM4EMAPTPTGS1
SCHEMBL24861953 0.91 PTGER4 (0.62) PTGER4PTGER2KDM4EMAPTPTGS1
SCHEMBL30331185 0.91 PTGER4 (0.62) PTGER4PTGER2KDM4EMAPTPTGS1
SCHEMBL876593 0.88 PTGER4 (0.60) PTGER4PTGER2KDM4EMAPTPTGS1
SCHEMBL15239116 0.88 PTGER4 (0.69) PTGER4PTGER2KDM4EMAPTLMNA
SCHEMBL876516 0.87 PTGER4 (0.69) PTGER4PTGER2KDM4EMAPTLMNA
SCHEMBL876384 0.85 PTGER4 (0.57) PTGER4PTGER2KDM4EMAPTPTGS1
SCHEMBL26417055 0.85 PTGER4 (0.55) PTGER4PTGER2KDM4EMAPTLMNA
SCHEMBL29720444 0.85 PTGER4 (0.55) PTGER4PTGER2KDM4EMAPTLMNA
SCHEMBL876698 0.85 PTGER4 (0.70) PTGER4PTGER2KDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2619182-B1 PHARMACEUTICAL COMPOSITION EISAI R&D MAN CO LTD (JP) 2016-11-09 EP disclosed
EP-3061751-A1 PHARMACEUTICAL COMPOSITION Eisai R&D Management Co., Ltd. (JP) 2016-08-31 EP disclosed
US-9000024-B2 Pharmaceutical composition EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-07 US disclosed
US-20140155452-A1 PHARMACEUTICAL COMPOSITION EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-06-05 US disclosed
US-20130237578-A1 PHARMACEUTICAL COMPOSITION EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-09-12 US disclosed
EP-2619182-A1 PHARMACEUTICAL COMPOSITION Eisai R&D Management Co., Ltd. (JP) 2013-07-31 EP disclosed
WO-2012039972-A1 PHARMACEUTICAL COMPOSITION EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155452-A1 PHARMACEUTICAL COMPOSITION CYP3A5, CYP2C19, CYP3A7 PTGER4 147/4885PTGER2 131/4885KDM4E 3744/4885
US-20130237578-A1 PHARMACEUTICAL COMPOSITION CYP3A5, CYP2C19, CYP3A7 PTGER4 147/4885PTGER2 131/4885KDM4E 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.